Prevention by Lamivudine of Hepatocellular Carcinoma in Patients Infected with Hepatitis B Virus.
- Author:
Heon Ju LEE
1
;
Ryul EUN
;
Byung Ik JANG
;
Tae Nyeun KIM
Author Information
1. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. hjlee@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
Lamivudine;
Chronic hepatitis B;
Hepatocellular carcinoma;
Prevention
- MeSH:
Alcohol Drinking;
Carcinoma, Hepatocellular*;
Case-Control Studies;
Follow-Up Studies;
Hepatitis B virus*;
Hepatitis B*;
Hepatitis B, Chronic;
Hepatitis*;
Humans;
Incidence;
Lamivudine*;
Platelet Count;
Prevalence
- From:Gut and Liver
2007;1(2):151-158
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This study evaluated the prevention by lamivudine of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. METHODS: Lamivudine therapy was administered to 879 of the 2,511 patients who satisfied our analysis inclusion criteria. A Cox regression model revealed that four factors increased the prevalence of HCC: gender (females; OR=0.53, p=0.006), age (> or =40 years; OR=4.64, p<0.001), platelet count (> or =100x10(3)/mm3; OR=0.35, p<0.001), and alcohol consumption (> or =80 g/day; OR=1.79, p=0.004). Five hundred and eighty-nine patients in the lamivudine-treated group and 589 patients in the control group were selected for a matched case-control study. The mean follow-up periods were 2.8 and 5.1 years in the lamivudine-treated and control groups, respectively. RESULTS: HCC occurred in 10 patients (1.7%) of the lamivudine group, with an incidence rate of 0.61% patients/year, and in 65 patients (11.0%) of the control group, with an incidence rate of 2.16% patients/year. The cumulative incidence of HCC was lower in the lamivudine group than in the control group (p=0.0117, log-rank test). CONCLUSIONS: Lamivudine can reduce the incidence of HCC in patients suffering from chronic hepatitis B.
